Background: Cystic fibrosis (CF) results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride channel localized at the plasma membrane of diverse epithelia. The most common mutation leading to CF, ⌬F508, occurs in the first nucleotide-binding domain (NBD1) of CFTR. The ⌬F508 mutation disrupts protein processing, leading to a decreased level of mutant channels at the plasma membrane and reduced transepithelial chloride permeability. Partial correction of the ⌬F508 molecular defect in vitro is achieved by incubation of cells with several classes of chemical chaperones, indicating that further investigation of novel small molecules is warranted as a means for producing new therapies for CF.
Introduction
Cystic fibrosis (CF) is a lethal human genetic disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (1) (2) (3) . The protein encoded by the CFTR gene is a cAMP-regulated chloride channel located in the apical membrane of epithelial cells in various tissues (4) . CFTR is a member of the ABC transporter superfamily of proteins that are involved in translocation of a diverse set of substrates across biological membranes in both prokaryotes and eukaryotes (5) . It has been proposed that a functional ABC transporter has a minimal structural requirement of two membrane-spanning domains (MSDs) and two cytosolic nucleotide binding domains (NBDs) that can be present in a single polypeptide or formed by a membrane-associated multiprotein complex (6) .
The most common mutation causing CF is the in-frame deletion of a phenylalanine at position 508 (⌬F508) in the first nucleotide binding domain of CFTR (NBD1), occurring in ϳ70% of CF chromosomes. The ⌬F508 mutation impairs processing of CFTR in the endoplasmic reticulum (ER), resulting in decreased levels of mature CFTR at the plasma membrane and defective cAMP-regulated chloride conductance in diverse epithelia. A large fraction of CFTR⌬F508 fails to fold into a native conformation, resulting in its retention by the ER-associated quality control and subsequent degradation with the participation of the cytoplasmic proteasome (7) (8) (9) (10) (11) . In addition to the biosynthetic defect, the ⌬F508 mutation also affects the chloride channel function of CFTR, reducing the channel open probability (P ) (12) (13) (14) . Partial reversal of the processing defect resulting from ⌬F508 can be achieved by altering conditions in which cultured cells expressing the mutant CFTR are incubated. For example, addition of glycerol in high concentration to the culture media (15, 16) or reduction of the cell culture incubation temperature (17) partially restore CFTR⌬F508 processing. Additionally, several CFTR activators have been developed that can enhance activity of the mutant chloride channel at the plasma membrane (18, 19) .
The ⌬F508 mutation is thought to affect the folding of the NBD1 domain polypeptide (20, 21) , leading to defective processing and function of the mutant CFTR⌬F508 protein. The precise effect of ⌬F508 on NBD1 structure is unknown because a crystal structure of CFTR NBD1 is currently unavailable. Dimerization of NBDs has been observed for the subunits of bacterial ABC transporters HisP and MalK (22) (23) (24) (25) , and for the ER and peroxisomal localized ABC transporters (26) . Thus, dimerization of CFTR NBDs may similarly occur, and the ⌬F508 mutation may interfere with NBD1 folding such that dimerization is defective.
Using the yeast two-hybrid system, we have established that CFTR NBD1 is able to interact with itself in vivo, and that the ⌬F508 mutation impairs this interaction. We have used the yeast two-hybrid assay in a drug screening format to identify a novel limonoid compound that reverses the ⌬F508 dimerization defect in yeast and promotes increased cAMP-stimulated chloride current from mammalian cells expressing CFTR⌬F508. The identification of compounds that specifically target and rescue CFTR⌬F508 could lead to the development of a therapy for CF.
Materials and Methods

Plasmid Construction and Yeast Strains
The plasmid pSwick-CFTR containing the fulllength wild-type CFTR cDNA was obtained from M. Welsh (University of Iowa) and amplified by the polymerase chain reaction (PCR) with the appropriate oligonucleotide primers to generate a DNA segment corresponding to CFTR NBD1 and upstream linker region, T351-F650. The T351-F650 segment was cloned in-frame into the carboxy-terminus of the GAL4 DNA-binding domain on a yeast plasmid pBDGAL4 (Stratagene Cloning Systems, La Jolla, CA, USA). The resulting plasmid (pBDNBD1) contains a fusion protein consisting of the GAL4 DNA binding domain fused to CFTR NBD1 (T351-F650) expressed under the control of the yeast ADH1 promoter and also contains the yeast selectable marker TRP1 and the 2 origin of replication. The same segment of CFTR NBD1 was also cloned in-frame into the GAL 4 activation domain on pADGAL4 (with the yeast selectable marker LEU2 and 2 origin) to produce pADNBD1. Both plasmids pBDNBD1 and pADNBD1 were introduced by transformation into yeast strain YGR-2 (HybriZap Two Hybrid Cloning Kit, Stratagene), genotype: Mat␣, ura3 -52, his3-200, ade2-101, lys2-801, trpl-901, leu2-3, 112 , gal4-542, gal80-538, LYS2::UAS GAL1 -TATA GAL1 -HIS3 URA::UAS GAL4 17mers(x3) TATA CYC1 -lacZ) and transformants were selected on selective media lacking tryptophan and leucine to produce the yeast strain YRG2-WT. Plasmids identical to pBDNBD1 and pADNBD1, but containing CF-causing mutations (⌬F508, ⌬I507, S549R, and G551D) were similarly constructed (producing pBD⌬F, pAD⌬F, pBD⌬I507, pAD⌬I507, pBDS549R, pADS549R, pBDG551D, pADG551D). Plasmids pBD⌬F and pAD⌬F were introduced by transformation into yeast strain YGR-2 to produce yeast strain YRG2-⌬F. Other yeast strains expressing GAL4/CFTR NBD1 fusion proteins containing CF-causing mutations were constructed by transformation with the cognate pBDNBD1 and pADNBD1 derivatives. The YRG-2 control strain used in Figure 4 contained pBDGAL4 (lacking CFTR NBD1 sequences) and pADNBD1. The DNA structure of the constructs was confirmed by DNA sequence analysis. Fig. 1 . Effect of CF mutations on NBD1 interaction in the yeast two-hybrid system. The yeast strain YRG-2 was cotransformed with the pBDNBD1 and pADNBD1 plasmids as indicated. pADNBD1 and pBDNBD1 were co-expressed with pBDGal4 p53 and pADGal4 T-antigen, respectively, as controls. Equal aliquots of serial dilutions of each yeast strain were plated on -Leu -Trp medium (A) and on -Leu -Trp -His selective medium containing 5 mM AT (B). Triangles indicate increasing dilution of each culture. Plates were incubated for 3 days at 30ЊC. spots visualized by spraying with 50% H 2 SO 4 solution followed by heating, or with UV lamp (254 and 366 nm). (Table 1) showed proton signals at ␦7.36 (d, J ϭ 1.6 Hz), 7.13 (s), and 6.18 (d, J ϭ 1.6 Hz) which were attributed to a furan ring (27) , while proton signals at ␦5.93 (d, J ϭ 9.5 Hz) and 7.08 (d, J ϭ 9.5 Hz) were attributed to H-2 and H-3, respectively. Many other proton signals were observed including four methyl groups between ␦1.41-0.80. The 13 C NMR spectrum (Table 2) showed the presence of a carbonyl group at ␦200.8, and carbon signals at ␦131.6 and 151.9 were attributed to C-2 and C-3, respectively. Four methyl signals were also observed between ␦22. 5-17.8 . The COSY spectrum showed proton-proton correlations such as H-2 to H-3; H-6 to H-5 and H-7; H-16 to H-15 and H-17; H-11 to H-12; and H-22 to H-23. HMBC spectrum showed pertinent cross-correlation peaks between H-19 and C-1, C-5, C-9, and C-10; H-29 and C-3, C-4, C-5, and C-28; as well as between H-11 and C-8, C-10, C-12, and C-13. The structure of TS1 was determined on the basis of all the above NMR data. The stereochemistry of TS1 was determined with the aid of NOE's correlations as shown in Figure 3B . The coupling constants observed in the 1 H NMR spectrum were also very useful. The large coupling constant (J ϭ 12.6 Hz) between H-5 and H-6 clearly showed that both protons were in trans position, and the smaller one (J ϭ 3. between H-7 and the carbonyl (␦167.1), C-5, C-6, and C-8 indicated that the ester group was linked at C-7. Structure TS2 has thus been assigned on the basis of this spectral data.
Spectroscopic Analysis of Limonoid Compounds
Yeast Two-Hybrid Assay
YRG-2 yeast strains expressing the pADNBD1 and pBDNBD1 variants were plated on selective medium lacking histidine as described by the supplier (Stratagene), supplemented with 1.5-5 mM 3-amino-1,2,4-triazole (AT) and incubated at 30ЊC for 3 days.
Bioassay-Directed Fractionation
Leaves of Trichilia sp. c.f. rubescens Oliv. were collected from Korup reserve, South West Province of Cameroon. Air-dried powdered leaves (2.7 kg) were macerated in acetone (8 l) at room temperature for 3 ϫ 2 days. Filtration and vacuum concentration led to a dark greenish extract (154 g). This extract was dissolved in a mixture of H 2 O-MeOH (9:1) and subsequently extracted with hexane and CH 2 Cl 2 to afford 47.5 g and 42.5 g of the hexanesoluble fraction and CH 2 Cl 2 -soluble fraction, respectively. Vacuum liquid chromatography on SiO 2 of the CH 2 Cl 2 extract (which contained the bioactivity) eluted with gradients of EtOAc in hexane led to five main fractions (F1-F5) of increasing polarity. Only fractions F3 and F4 yielded positive results in the yeast two-hybrid bioassay. F3 (1.2 g) eluted with hexane-EtOAc (8:2) was then passed through a silica gel column using CH 2 Cl 2 to give a mixture that was further purified on chromatotron using Me 2 CO-CH 2 Cl 2 (2:98) to give TS2 (80 mg) and a mixture of unresolved compounds. F4 (0.9 g), also eluted with hexaneEtOAc (8:2), was purified in the same way as fraction F3 to yield TS1 (40 mg) and TS3 (133 mg). An additional purification of TS1 and TS3 by gel permeation through Sephadex LH-20 (to remove chlorophyll) was required to obtain pure analytical samples.
Experimental Procedures for Structure Determination
Melting points were recorded with a kohfler hot stage 277938 and are uncorrected. Optical rotations were measured on an AA Series automatic polarimeter POLAAR-2000, while the IR spectra were recorded on a JASCO FT-IR-410 spectrophotometer. 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded in CDCl 3 on BRUKER DPX-400 spectrometer. The chemical shifts (␦) are reported in parts per million (ppm) relative to chloroform signals as reference (␦ H ϭ 7.26 and ␦ C ϭ 77.0) and coupling constants (J values) are given in Hertz.
1 H-1 H COSY, NOE's, HMBC, and HMQC experiments were recorded with gradient enhancements using sine-shaped gradient pulses. Mass spectra were recorded in the positive EI mode on a JEOL JMS-700 instrument. Column chromatography, run on Merck Si gel 60, and gel permeation chromatography on Sephadex LH-20 were used for isolation and purification. TLC were carried out on silica gel 60 F 254 (Merck) precoated plates and Tables 1 and 2 ) of TS3 were again closely related to those of TS1. The hydroxyl group present in the IR spectrum of TS1 was absent in that of TS3, while additional sp 2 carbon atoms appeared in the 13 C NMR spectrum of TS3 at ␦150.4 and 100.7. This clearly showed that dehydration occurred in TS1 to give TS3. The proposed structure was in agreement with correlations observed in COSY, NOE's, HMQC, and HMBC spectra.
Cell Culture
Fischer rat thyroid (FRT) cell lines stably expressing either CFTR or CFTR⌬F508 were a generous gift from M. Welsh (University of Iowa) (28) . FRT cells were maintained at 37ЊC in a humidified, 5% carbon dioxide atmosphere. Growth medium was Coon's modification of Ham's F-12 (Sigma Chemical Co., St. Louis, MO, USA) supplemented with 5% Fetal Bovine Serum (Summit Biotechnology, Ft. Collins, CO, USA) and 100 U/ml of penicillin G sodium, 100 U/ml of streptomycin sulfate, and 
Electrophysiology
For functional studies, FRT cell lines stably expressing CFTR variants were plated at 2.5 ϫ 10 5 cells/cm 2 on Millicell-HA cell culture inserts (pore size 0.45 m, Millipore Co., Bedford, MA, USA) and incubated under the conditions described above. Transepithelial resistance was monitored daily (Millicell Electrical Resistance System, Millipore) and were typically higher than 3000 ⍀/cm 2 after 4 days. FRT monolayers were mounted on modified Ussing chambers (Jim's Instruments, Iowa City, IA, USA) and continually gassed with O 2 . Temperature was maintained at 37ЊC. Transepithelial chloride gradient was imposed by bathing the basolateral surface containing (in mM): 135 NaCl, 1.2 CaCl 2 , 1.2 MgCl 2 , 2.4 K 2 HPO 4 , 0.6 KH 2 PO 4, 10 HEPES and 10 dextrose, pH 7.4, and the apical surface with a similar solution, except that 135 mM sodium gluconate replaced the 135 mM NaCl, bringing the chloride concentration to 4.8 mM. Under these conditions, the chloride resting potential, according to Nernst equation is 90 mV. The potential difference and the fluid resistance between the potential sensing electrodes were compensated. The transepithelial voltage was 
Results
Yeast Two-Hybrid Analysis Shows That CFTR NBD1 Forms Homodimers In Vivo and CF Mutations Affecting CFTR Processing Disrupt This Interaction
Using the yeast two-hybrid system (29), we tested whether CFTR NBD1, in the absence of other CFTR domains, could form homodimers and thereby activate transcription of the HIS3 reporter gene. CFTR NBD1 and the upstream linker region between the first transmembrane domain and NBD1 (aa residues 351-650) were fused in frame with the GAL4 activation domain (AD) and with the GAL4 DNA binding domain (BD), resulting in plasmids pADNBD1 and pBDNBD1, respectively. Cotransformation of the yeast strain YRG-2 with both plasmids (to produce YRG2-WT) conferred a HISϩ phenotype to the yeast, indicating that NBD1 is competent to form homodimers in vivo (Fig. 1) . To assess the effect of CF-causing mutations on NBD1 homodimerization, ⌬I507, ⌬F508, S549R, and G551D were each introduced into NBD1 in both pADNBD1 and pBDNBD1. As shown in Figure 1B , the mutations ⌬F508, ⌬I507, and S549R, resulted in a HIS-phenotype, indicating defective NBD1 dimerization. The CF-causing mutation G551D, which impairs chloride channel function, but not processing of CFTR, did not result in defective NBD1 dimerization in yeast (Fig. 1) .
Use of the Yeast Two-Hybrid System to Screen for Compounds That Restore NBD1⌬F508 Dimerization in Yeast
The results presented suggest that mutations in NBD1 that affect CFTR processing are effectively modeled in yeast. Accordingly, we reasoned that a yeast strain containing derivatives of plasmids pADNBD1 and pBDNBD1 with the ⌬F508 mutation clamped to zero (Voltage Clamp Channel Module, model 558C-5, Dept. of Bioengineering, University of Iowa), transepithelial resistance was monitored by recording of current deflections in response to 2-sec pulse of 1-5 mV every 50 sec. The short circuit currents were recorded continuously on a charter recorder (Model SR6335, Western Graphtec, Inc., Irvine, CA, USA). After a stable baseline current was observed (usually within less than 10 min), the channel was activated with cAMP agonists and the current reflecting the flow of Cl Ϫ promoted by its concentration gradient (I sc ) was recorded as downward deflection. The I sc was calculated as the difference between the sustained phase of the response and the baseline. (YRG2-⌬F) would have potential as a drugscreening tool in the identification of new small molecules that restore mutant NBD1 folding and/ or dimerization and promote growth of YRG2-⌬F on selective medium. As a source of diverse small molecules for drug screening, we investigated natural product compounds present in plants. Plants are rich in chemical diversity and are an established source of active pharmacologic compounds (30) . Direct testing of plant leaf material using the yeast two-hybrid assay allowed large numbers of samples to be screened at a relatively low cost as compared to synthetic chemical libraries. A paper punch was used to sample plant leaves of approximately 600 different species within a segment of tropical rainforest in the Korup National Park of Cameroon. The plant leaf discs were placed in an array on a lawn of YRG2-⌬F yeast in a plate containing selective medium lacking histidine (Fig. 2) . Small molecules within the plant discs diffused through the agar into the YRG2-⌬F yeast strain, and compounds with activity to enhance the folding of mutant NBD1, or to enhance mutant NBD1 dimerization, promoted growth of the yeast on selective medium lacking histidine. A plant of the genus Trichilia sp. c.f. rubescens Oliv. (Meliaceae) was identified as one of eight species testing positive in the bioassay (Fig. 2) .
Isolation of Novel Limonoid Compounds That Restore Dimerization to NBD1⌬F508
Leaf material from Trichilia sp. c.f. rubescens Oliv. was fractionated using the YRG2-⌬F bioassay to direct the purification of the active compound(s). Three structurally related limonoid compounds, designated TS1, TS2, and TS3, were subsequently purified and the structure of each determined by spectroscopic analysis including 2D NMR techniques, as described in Materials and Methods (Tables 1 and 2 , Fig. 3 ). Each purified limonoid compound was tested using the YRG2-⌬F yeast strain (Fig. 4A) and also a control yeast strain in which the NBD1 domain was absent from the GAL4 fusion construct (Fig. 4B ). TS3 demonstrated a robust activity in the YRG2-⌬F yeast bioassay; comparatively lower activity was associated with TS2, and no activity was (Table 1) , 13 C NMR spectra (Table 2) , and IR spectra as described in Materials and Methods. (B) NOE's correlation of TS1. greatest potency in correcting the growth defect of the YRG2-⌬F yeast strain, also had a significant effect in increasing the cAMP-stimulated chloride channel current of mammalian cells expressing CFTR⌬F508. TS3 had no effect on cAMP-stimulated chloride currents of FRT monolayers not expressing CFTR (Fig. 8) .
To establish the duration of the TS3-mediated enhancement of CFTR⌬F508 chloride current following removal of the TS3 compound from treated cells ("wash out"), transepithelial currents were measured from TS3-treated monolayers after incubation in compound-free medium for increasing periods of time. As expected, prolonged incubation of TS3-treated monolayers in TS3-free growth medium (24 hr) resulted in a gradual decrease of chloride current, down to control values (Fig. 5A) . However, when monolayers were treated with 5 M TS3 for 48 hr followed by removal of TS3 from the growth medium for only 9 hr, the cAMPstimulated chloride currents were increased to 1.8-fold relative to control monolayers, a value greater than the 37% increase observed in the absence of the "wash out" (Fig. 5) . These results indicate that enhancement of cAMP-stimulated chloride channel conductance by TS3 is further increased by the removal of TS3 prior to measurements of chloride channel conductance.
TS3 Has a Modest Effect in Increasing Chloride Permeability of FRT Monolayers Expressing Wild-Type CFTR
To determine if the effect of TS3 was specific to CFTR⌬F508, we incubated FRT monolayers stably expressing wild-type CFTR (FRT-WT) in the presence of 5 M TS3 for 48 hr and measured the cAMPactivated transepithelial chloride current. TS3 treatment increased the chloride current of monolayers expressing wild-type CFTR (CFTR wt) by 19% over control monolayers (Fig. 6) . Incubation of TS3-treated FRT-WT monolayers in TS3-free medium for 9 hr did not result in further increase of the chloride currents (Fig. 6) .
Effect of TS3 on CFTR and CFTR⌬F508 Chloride Channel Function
Results in Figure 5 indicate that 5 M TS3 could have a positive effect on CFTR⌬F508 processing and an inhibitory effect on chloride channel function. To directly test if TS3 could inhibit CFTR channels, FRT-⌬F and FRT-WT polarized monolayers were incubated for 6 hr in the presence of 5 M TS3, a period shorter than necessary to detect a possible rescue of the defective processing, but presumably sufficient to allow intracellular accumulation of TS3. The TS3 treatment for 6 hr resulted in a significant inhibition of the CFTR⌬F508 chloride currents, to 33% of the control (Fig. 7) . The chloride currents of CFTR wt were inhibited to a lesser extent, to 79% of control. TS3 thus partially inhibited both CFTR wt and CFTR⌬F508 function when present detected for TS1 (Fig. 4A) . CPX (8-cyclopentyl-1, 3-dipropylxanthine), a CFTR activator (31) shown to interact with NBD1 of CFTR⌬F508 (32), did not present a detectable activity in the yeast bioassay (Fig. 4A) . TS1, TS2, and TS3 did not promote growth of the control yeast strain (Fig. 4B) , indicating that the effect of TS2 and TS3 observed for YRG2-⌬F is mediated by the NBDs. TS2 and TS3 also did not affect the growth of YRG2-WT (data not shown), however, wild-type NBD1 dimerizes readily in this strain (resulting in a strong HISϩ phenotype), which may have precluded detection of a growth effect mediated by these compounds. Although the mechanism of action of TS2 and TS3 in correcting the YRG2-⌬F growth defect is unknown, we hypothesized that these compounds could possibly act as chemical chaperones, interacting with and facilitating the folding of NBD1⌬F508 and restoring the NBD1 interaction. The purified limonoids were therefore tested for rescue of the low chloride permeability defect presented by cells expressing CFTR⌬F508.
The Limonoid TS3 Is Effective in Increasing the Chloride Permeability of FRT Monolayers Expressing CFTR⌬F508
We tested the effect of TS1, TS2, and TS3 in correcting defective cAMP-stimulated chloride permeability in FRT cells stably expressing CFTR⌬F508 (FRT-⌬F). Treatment periods longer than 24 hr are usually necessary for assessment of the efficacy of interventions designated to rescue the CFTR⌬F508 processing defect. Polarized FRT-⌬F monolayers were incubated for 48 hr in the presence of a range of concentrations of each limonoid compound to assess toxicity. TS2 was the most toxic of the three compounds, leading to decreased transepithelial resistance (Ͻ170 Ohms/cm 2 ) of polarized FRT monolayers at concentrations higher than 2 M. TS1 and TS3 were toxic at concentrations higher than 10 M. To test the effect of TS1, TS2, and TS3 on the functional activity of CFTR⌬F508, monolayers of polarized FRT cells expressing CFTR⌬F508 (FRT-⌬F) were incubated in the presence of subtoxic concentrations of each compound for 48 hr and the transepithelial chloride currents were assayed in Ussing chambers, following stimulation with cAMP agonists. In control experiments, FRT-⌬F monolayers were treated with equivalent concentration of DMSO. A low level of cAMP-stimulated chloride current was observed for the FRT-⌬F cell line, approximately 2.5 A/cm 2 (Fig. 5A) . Treatment of FRT-⌬F monolayers with 1-5 M TS1 or 0.5-2 M TS2 was without effect on the cAMP-stimulated chloride currents (data not shown). Treatment of FRT-⌬F monolayers for 48 hr with 1 or 5 M TS3 resulted in 38% and 27% increases, respectively, over DMSO-treated control monolayers (Fig. 5A) . Longer incubation of monolayers with 5 M TS3 for 48-72 hr gave similar results (data not shown). Thus TS3, the limonoid compound that had the for a short incubation period that would preclude a possible positive effect on processing.
Addition of 5-15 M TS3 directly to FRT-⌬F monolayers mounted in Ussing chambers, either before or after stimulation with cAMP agonists, did not increase CFTR⌬F508 chloride current (data not shown), nor did a short incubation of FRT-⌬F monolayers with TS3 for only 6 hr (Fig. 7) . These results, taken together with the results shown in Figure 5 , suggest that the effect of TS3 to increase chloride conductance of cells expressing CFTR⌬F508 is not immediate as observed with CFTR channel activators such as CPX and genistein (32) (33) (34) , and is more likely to result in a time-dependent effect on CFTR processing rather than function. However, we were unable to detect in a Western blot an increase in the amount of the fully glycosylated form of CFTR⌬F508 in response to incubation of the cells with TS3 (data not shown), indicating that enhancement of processing by TS3 is small.
TS3 Treatment Combined With Genistein Activation Effectively Rescues the Chloride Impermeability of FRT-∆F
Genistein is an activator of CFTR that has been shown to increase the open time probability P of the CFTR⌬F508 channel (13, 18, 35) . The presence of 50 M of genistein during chloride channel activation significantly enhances chloride currents of DMSOand TS3-treated FRT-⌬F monolayers by 100% and 51%, respectively (Fig. 8) . A 3-fold increase in chloride channel conductance in FRT-⌬F cells is obtained when 50 M of genistein is used to activate TS3-treated monolayers (Fig. 8) . The effects of TS3 and genistein are thus additive, suggesting that enhanced restoration of CFTR⌬F508 functional activity can be attained with the use of small molecules having complementary effects in restoring CFTR⌬F508 processing and function. Furthermore, the magnitude of the CFTR⌬F508 chloride current increase resulting from 5 M TS3 treatment was similar to the effect of activation with 50 M genistein alone (Fig. 8) .
the plasma membrane. CFTR⌬F508 that is correctly located at the plasma membrane has decreased stability in relation to CFTR wt (38) (39) (40) ; however, the mutant protein still retains at least one-third of the chloride channel activity of wild-type CFTR (14) .
Using the yeast two-hybrid system, we have determined that CFTR NBD1 forms dimers in vivo in yeast and that ⌬F508 impairs the ability of NBD1 to
Discussion
The molecular basis for the effect of the ⌬F508 mutation on CFTR processing is unknown, although it is generally accepted that the mutation causes misfolding of the CFTR⌬F508 polypeptide within the ER (36), resulting in retention and degradation by the ER-associated quality control mechanism (37) and substantially reduced levels of CFTR⌬F508 at form dimers. Because dimerization of NBDs has been demonstrated for several other ABC transporters (22, 25, 26, (41) (42) (43) , the dimerization of NBD1 that we observe in yeast may represent a bona fide interaction between NBD1 domains of CFTR molecules that occurs in vivo in mammalian cells during the normal processing of CFTR. The quaternary structure of CFTR is currently a subject of debate, although previous experiments have suggested that CFTR is a monomer (44) . Recently, however, it has been shown that CFTR has the appearance of dimers at the plasma membrane (45) and in reconstituted liposomes (46) . Dimerization has also been shown to regulate CFTR functional activity (47) . The dimeric form may thus be transient and represent only a fraction of the CFTR within the cell.
Our results indicate that CFTR processing is associated with folding of wild-type NBD1 into a structure that is competent to form homodimers. CF mutations affecting CFTR processing (⌬F508, ⌬I507, and S549R) resulted in defective CFTR NBD1 dimer formation in yeast. In contrast, the G551D mutation, which does not impair CFTR processing, had no effect on NBD1 association. The correlation between mutations causing defective processing of CFTR and defective dimerization of NBD1 in yeast further suggests that dimerization of CFTR, mediated in part by NBD1, could be associated with CFTR processing. Alternatively, it is possible that NBD1 dimer formation is a property of NBD1 that has folded into a native state, thereby becoming competent to selfassociate. Interestingly, dimerization of the NBD domains of peroxisomal ABC "half-transporters" have also been shown in the yeast two-hybrid system, and dimerization was disrupted by two mutations associated with X-linked adrenoleukodystrophy (43) . Homodimerization of NBD1 in yeast could be a consequence of the absence of NBD2 because allosteric interaction between NBD1 and NBD2 has been observed (48) . However, interaction between NBD1 and NBD2 using the yeast two-hybrid system has not been observed (49) .
Although the biological significance of CFTR NBD1 dimerization in vivo is unknown, the yeast two-hybrid assay provides a means to assay a growth-defective phenotype for a CF-causing mutation in yeast, and to detect the activity of bioactive small molecules that reverse the growth defect. We have used this assay to screen a biodiverse collection of tropical plants. Bioassay-directed fractionation from Trichilia sp. c.f. rubescens Oliv. yielded a pure limonoid compound TS3 with activity to correct the growth defect of YRG2-⌬F. Limonoids are a group of highly oxidized terpenoids present in several species of the genus Trichilia (50-57). Several biological activities have been shown for limonoid compounds: insect antifeedant (58-60), inhibition of cell adhesion (61), toxicity to DNA repair deficient yeast (62) , and antimicrobial activity (63) . Possibly other limonoids from related Trichilia species or derivatives of TS3 have activity to correct the ⌬F508 defect. Because TS3 demonstrated activity to correct both the ⌬F508 growth defect in yeast and also the chloride permeability defect in FRT-⌬F cells, the results strongly suggest that the effect of the ⌬F508 mutation on NBD1 is effectively modeled in yeast, and that activity of compounds to correct the molecular defect may be assayed using the yeast two-hybrid system. Enhancement of CFTR⌬F508 chloride current by TS3 treatment was increased when the cells were incubated in TS3-free medium prior to measurement of chloride conductance. These results lead us to hypothesize that increased chloride conductance resulting from a putative positive effect of TS3 to increase CFTR⌬F508 levels at the plasma membrane may be countered by an inhibitory effect of TS3 on CFTR⌬F508 function. In support of this notion, an inhibitory effect of TS3 was also noted when FRT-⌬F monolayers were incubated with 5 M TS3 for 6 hr. We did not observe enhancement of CFTR⌬F508 chloride current in CFTR cells expressing CFTR⌬F508 when cells were incubated with limonoid compounds TS1 or TS2. As shown in Figure 3A , these compounds differ from TS3 only with respect to the functional group associated with C7 position, which is hydrogen in TS3. This suggests that the activity of TS3 to correct the NBD1 dimerization defect in yeast and also the activity to enhance chloride conductance from cells expressing CFTR⌬F508 depends at least in part on the structural determinants presented at C7.
TS3-mediated increase in FRT-⌬F chloride currents required that monolayers were incubated for at least 48 hr with TS3, consistent with the time required to detect the functional activity associated with an increase in processed CFTR⌬F508. In contrast, short incubations of FRT-⌬F cells with TS3 for periods of 6 hr or less did not result in a TS3-mediated increase in FRT-⌬F chloride current. The TS3 compound therefore does not appear to activate CFTR⌬F508 in the same manner as genistein or CPX, which induce a rapid increase in the functional activity of CFTR⌬F508 already localized at the plasma membrane. Instead, TS3 most likely promotes an increase of CFTR⌬F508 channels at the plasma membrane, detectable as an increase in cAMP-stimulated chloride currents, which could result from improved processing at the ER or increased stability of the small fraction of the mutant protein present at the plasma membrane. A TS3-mediated increase in the amount of processed CFTR⌬F508 at the plasma membrane was not detected by Western blot analysis, suggesting that the effect of TS3 to correct processing is small. However, in analogous studies involving treatment of MDCK cells expressing CFTR⌬F508 with the anticancer drug doxorubicin, it was similarly observed that a drug-mediated increase in cAMP-stimulated chloride channel activity (64) corresponded to only a small improvement of CFTR⌬F508 processing, which was not readily detectable by Western blot analysis.
It has been estimated that 10% of wild-type CFTR activity can rescue the electrolyte defect in a CF tissue (65) , representing roughly a 10-fold increase in CFTR⌬F508-mediated chloride permeability. TS3 did not mediate this level of rescue of CFTR⌬F508; however, a 3-fold increase in the cAMP-stimulated chloride current in FRT cells expressing CFTR⌬F508 was attained by treatment with both genistein and TS3.
An effective strategy to increase CFTR⌬F508 chloride conductance may thus involve a combination of small molecules that are active in rescuing CFTR⌬F508 processing and functional defects. TS3 represents a novel class of compounds that can interact with NBD1 ⌬F508 in vivo and promote an increase in cAMPstimulated chloride permeability of cells expressing CFTR⌬508. The yeast two-hybrid assay described here provides a means to identify additional new small molecules that target NBD1 and have activity to increase the chloride permeability of cells expressing CFTR⌬F508.
